Furthermore, the SELECT trial10 showed that semaglutide reduced major adverse CV events (MACE) in individuals with overweight or obesity without diabetes.10 These findings suggest a potential interaction between BMI and the cardioprotective effects of GLP-1 RAs. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.